Complement factor H Y402H decreases cardiovascular disease risk in patients with familial hypercholesterolaemia

European Heart Journal

Volumn 30, Issue 5, 2009, Pages 618-623

  Koeijvoets, Kristel C M C ^a   Mooijaart, Simon P ^b   Dallinga Thie, Geesje M ^c   Defesche, Joep C ^c   Steyerberg, Ewout W ^a   Westendorp, Rudi G J ^b   Kastelein, John J P ^c   Van Hagen, P Martin ^a   Sijbrands, Eric J G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Cardiovascular disease; Complement factor H; Familial hypercholesterolemia; Polymorphism

Indexed keywords

COMPLEMENT FACTOR H;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA POLYMORPHISM; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; WILD TYPE; AGE; CLINICAL TRIAL; EPIDEMIOLOGY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HYPERLIPOPROTEINEMIA TYPE 2; MIDDLE AGED; MULTICENTER STUDY; PROGNOSIS;

ADULT; AGE FACTORS; CARDIOVASCULAR DISEASES; COMPLEMENT FACTOR H; EPIDEMIOLOGIC METHODS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS;

EID: 63349101183     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehn568     Document Type: Article

References (30)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005:352:1685-1695.
2. Oksjoki R, Kovanen PT, Pentikäinen MO. Role of complement activation in atherosclerosis. Curr Opin Lipidol 2003:14:477-482.
3. Niculescu F, Rus HG. Complement activation and atherosclerosis. Mol Immunol 1999;36:949-955.
4. Vlaicu R, Niculescu F. Rus HG, Cristea A. Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque. Atherosclerosis 1985:57:163-177.
5. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001:158:1039-1051.
6. Rodríguez de Córdoba S. Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascaza M, Sánchez-Corral P. The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol 2004;41: 355-367.
7. Oksjoki R, Jarva H, Kovanen PT, Laine P, Meri S, Pentikäinen MO. Association between complement factor H and proteoglycans in early human corona7 atherosclerotic lesions: implications for local regulation of complement activation. Arteriosder Thromb Vase Bio 2003;23:630-636.
8. Wiggs JL Complement factor H and macular degeneration. The genome yields an important clue. Arch Ophthalmol 2006;124:577-578.
9. Klein RJ. Zeiss C. Chew EY, Tsai J-Y. Sackler RS, Haynes C, Henning AK. SanGiovanni JP, Mane SM, Mayne ST, Bracken MB, Ferris FL Ott J, Barnstable C, Hoh J. Complement factor H polymorphism in age-related macular degeneration. Science 2005;308:385-389.
10. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, Spencer KL, Kwan SY, Noureddine M, Gilbert JR, Schnetz-Boutaud N, Agarwal A, Postel EA, Pericak-Vance MA. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005;308:419-421.
11. Edwards AO, Ritter R III. Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science 2005:308:421-424.
12. The Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-572.
13. Thakkinstian A. Han P, McEvoy M, Smith W, Hoh J. Magnusson K, Zhang K, Attia J. Systematic review and meta-analyses of the association between complement factor H Y402H polymorphism and age-related macular degeneration. Hum Mol Genet 2006:15:2784-2790.
14. Friedman E. The role of the atherosclerotic process in the pathogenesis of age-related macular degeneration. Am J Ophthalmol 2000;130:658- 663.
15. Zee RYL, Diehl KA, Ridker PM. Complement factor H Y402H gene polymorphism, C-reactive protein, and risk of incident myocardial infarction, ischaemic stroke, and venous thromboembolism: A nested case-control study. Atherosclerosis 2006; 187:332 - 335.
16. Goverdhan SV, Lotery AJ, Cree AJ. Ye S. Complement factor H Y402H gene polymorphism in coronary artery disease and atherosclerosis. Atherosclerosis 2006:188:213-214.
17. Kardys I, Klaver CCW. Despriet DDG, Bergen AAB, Uitterlinden AG. Hofman A. oostra BA, van Duijn CM, de Jong PTVM, Witteman JCM. A common polymorphism in the complement factor H gene is associated with increased risk myocardial infarction. The Rotterdam Study. J Am Coll Cardiol 2006:47: 1568-1575.
18. Nicaud V, Francomme C. Ruidavets J-B. Luc G, Arveiler D, Kee F, Evans A, Morrison C, Blankenberg S, Cambien F, Tiret L. Lack of association between complement factor H polymorphisms and coronary artery disease of myocardial infarction. J Mol Med 2007:85:771 -775.
19. Stark K, Neureuther K, Sedlacek K, Hengstenberg W, Fischer M, Baessler A, Wiedmann S, Jeron A, Holmer S, Erdmann J, Schunkert H, Hengstenberg C. The common Y402H variant in complement factor H gene is not associated with susceptibility to myocardial infarction and its related risk factors. Clin Sci 2007:113:213-218.
20. Mooijaart SP. Koeijvoets KCMC, Sijbrands EJG, Daha MR, Westendorp RGJ. Complement Factor H polymorphism Y402H associates with inflammation, visceral acuity, and cardiovascular mortality in the elderly population at large. Exp Gerontol 2007:42:1116-1122.
21. Pai JK, Manson JE. Rexrode KM, Albert CM, Hunter DJ, Rimm EB. Complement factor H (Y402H) polymorphism and risk of coronary heart disease in US men and women. Eur Heart J 2007;28:1297-1303.
22. Brown MS, Goldstein JL A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34-47.
23. Sijbrands EJG, Westendorp RGJ, Defesche JC, de Meier PHEM, Smelt AHM, Kastelein JJP. Mortality over two centuries in large pedigree with familial hypercholesterolemia: family tree mortality study. BMJ 2001:322:1019-1022.
24. Melander O. Genetics of cardiovascular disease: interplay between common and rare alleles. J Hypertens 2008:26:394-395.
25. Jansen ACM. van Aalst-Cohen ES. Tanck MW, Trip MD, Lansberg PJ, Liem AH, Roeters van Lennep HWO. Sijbrands EJG, Kastelein JJP. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolemia: data in 2400 patients. J Intern Med 2004;256:482-490.
26. Fouchier SW, Defesche JC. Umans-Eckenhausen MAW, Kastelein JJP. The molecular basis of familial hypercholesterolemia in The Netherlands. Hum Genet 2001:109:602-615.
27. Kramer A, Jansen ACM, van Aalst-Cohen ES, Tanck MWT, Kastelein JJP, Zwinderman AH. Relative risk for cardiovascular atherosclerotic events after smoking cessation: 6-9 years excess risk in individuals with familial hypercholesterolemia. BMC Public Health 2006:23:262.
28. Spreidl WS, Exner M, Amighi J, Kastl SP, Zorn G, Maurer G, Wagner O, Huber K, Minar E, Wojta J, Schillinger M. Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis. Eur Heart J 2005;26:2294-2299.
29. Clark SJ, Higman VA, Mulloy B, Perkins SJ, Lea SM. Sim RB, Day AJ. His-384 allotypic variant of factor H associated with age-related macular degeneration has different heparin binding properties from the non-disease-associated form. J Biol Chem 2006;281:24713-24720.
30. Umans-Eckenhausen MAW, Sijbrands EJG, Kastelein JJP, Defesche JC. LDL-receptor gene mutations and cardiovascular risk in a large genetic cascade screening population. Circulation 2002;106:3031-3036.